MX9603570A - Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos. - Google Patents

Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos.

Info

Publication number
MX9603570A
MX9603570A MX9603570A MX9603570A MX9603570A MX 9603570 A MX9603570 A MX 9603570A MX 9603570 A MX9603570 A MX 9603570A MX 9603570 A MX9603570 A MX 9603570A MX 9603570 A MX9603570 A MX 9603570A
Authority
MX
Mexico
Prior art keywords
pharmacologically active
compositions
life
increasing
serum half
Prior art date
Application number
MX9603570A
Other languages
English (en)
Inventor
Jeffrey M Blaney
Fred Cohen
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of MX9603570A publication Critical patent/MX9603570A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan las composiciones y los métodos para incrementar la vida en suero de un agente farmacologicamente activo. Las nuevas composiciones son conjugados covalentes del agente farmacologicamente activo seleccionado y un ligando de enlace a transtiretina, tal como ácido tetrayodotiroacético, 2,4-6-triyodofeno,ácido flufenámico o similares.
MX9603570A 1994-02-23 1995-02-13 Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos. MX9603570A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20038794A 1994-02-23 1994-02-23
PCT/US1995/001815 WO1995022992A2 (en) 1994-02-23 1995-02-13 Method and compositions for increasing the serum half-life of pharmacologically active agents

Publications (1)

Publication Number Publication Date
MX9603570A true MX9603570A (es) 1997-03-29

Family

ID=22741505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603570A MX9603570A (es) 1994-02-23 1995-02-13 Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos.

Country Status (7)

Country Link
US (1) US5714142A (es)
EP (1) EP0802798A1 (es)
JP (1) JPH09509428A (es)
AU (1) AU1843295A (es)
CA (1) CA2184002A1 (es)
MX (1) MX9603570A (es)
WO (1) WO1995022992A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5727798A (en) * 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
US6740680B1 (en) * 1999-04-26 2004-05-25 Becton Pharma, Inc. Pharmaceutical compositions to tetrac and methods of use thereof
ATE330590T1 (de) * 1999-04-26 2006-07-15 Elliot Danforth Jr Pharmazeutische zusammensetzungen enthaltend tetrac sowie deren verwendungsverfahren
US6656730B1 (en) * 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7001905B2 (en) 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
FI107018B (fi) * 2000-04-06 2001-05-31 Ipsat Therapies Oy Dermatologinen käyttö ja valmiste
CA2447851C (en) * 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
ATE471931T1 (de) 2002-04-17 2010-07-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
WO2004006865A2 (en) * 2002-07-17 2004-01-22 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) * 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2005042697A2 (en) * 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
ES2391470T3 (es) * 2005-07-20 2012-11-27 Eli Lilly And Company Compuestos de fenilo
US8133907B2 (en) * 2005-07-20 2012-03-13 Eli Lilly And Company Pyridine derivatives as dipeptedyl peptidase inhibitors
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
US20090131380A1 (en) * 2007-11-16 2009-05-21 Pekka Heino Novel pharmaceutical composition for topical treatment of skin psoriasis and the treatment method thereof
WO2010108154A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
CN103339145A (zh) 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
EP2681238A2 (en) 2011-02-28 2014-01-08 Istituto di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo- Ospedale di Alta Specializzazione E di Rilievo Apoptosis-inducing molecules and uses therefor
SG10201601789TA (en) 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
CA2922407A1 (en) * 2012-08-31 2014-03-06 Kenneth M. Hargreaves A method to improve pharmacokinetics of drugs
US9029342B2 (en) 2012-09-17 2015-05-12 Board Of Regents Of The University Of Texas System Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
AU2015274574B2 (en) 2014-06-10 2019-10-10 Amgen Inc. Apelin polypeptides
US20160045609A1 (en) * 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3568411B1 (en) 2017-01-13 2024-03-06 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
MA68842B1 (fr) 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
FR3113904B1 (fr) 2020-09-08 2022-08-12 Innoverda Procédé de synthèse du 3,5-diiodo-4-hydroxy benzylalcool
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410633A (en) * 1980-09-25 1983-10-18 Corning Glass Works Method for the measurement of free thyroxine or 3,5,3'-triiodothyronine in a liquid sample
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5273885A (en) * 1992-07-31 1993-12-28 Syntex (U.S.A.) Inc. Conjugates of monophenyl thyroid analogs useful in assays

Also Published As

Publication number Publication date
AU1843295A (en) 1995-09-11
US5714142A (en) 1998-02-03
WO1995022992A2 (en) 1995-08-31
JPH09509428A (ja) 1997-09-22
CA2184002A1 (en) 1995-08-31
EP0802798A1 (en) 1997-10-29
WO1995022992A8 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
MX9603570A (es) Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos.
CA2234282A1 (en) Drug-resin complexes stabilized by chelating agents
IL106665A0 (en) Powder compositions for inhalation
ZA91353B (en) Pharmaceutical and cosmetic compositions
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
CA2229077A1 (en) Lipid metabolism improving agent
ZA969489B (en) Novel transfection agents and their pharmaceutical applications
CA2186260A1 (en) Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide
EP0687183A4 (en) SYNERGISTIC COMPOSITION CONSISTING OF A CD4-BASED PROTEIN AND ANTI-HIV-1 ANTIBODY, AND METHODS FOR THE USE THEREOF
MY131774A (en) Coated pesticidal agents, processes for their preparation and compositions containing them
CA2338358A1 (en) Compounds and compositions for delivering active agents
EP1093819A3 (en) Compounds and compositions for delivering active agents
IL115790A0 (en) Pharmaceutical compositions containing boronic ester and acid compounds and methods for the preparation thereof
SE9704546D0 (sv) Novel compounds
AU5162796A (en) Novel peptide derivatives
AU8033594A (en) Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof
ZA943520B (en) N-alkylthio polyamine derivatives as radioprotective agents.
AU633867B2 (en) Delivery of cytotoxic agents
MY132057A (en) Quinoxalinones, a process for their preparation and their use
BG100863A (en) Fibrin-specifil antibody and its use as an antithrombotic agent
GR3031118T3 (en) Novel seco-D steroids active in the cardiovascular system and pharmaceutical compositions containing same
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
TW344650B (en) Fungicidal compositions and the process for the preparation thereof
DE69527630D1 (de) Wasserlösliche glykolisierte derivate von 1,2-dithiinverbindungen
YU23498A (sh) Herbicidni 3,5-difluoropiridini